Genotropin and Ranitidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Genotropin (somatropin recombinant) and Ranitidine (ranitidine). Common drug interactions include infusion related reaction among females and heart rate increased among males.

The phase IV clinical study analyzes what interactions people have when they take Genotropin and Ranitidine. It is created by eHealthMe based on reports of 72 people who take the same drugs from the FDA, and is updated regularly.

What is Genotropin?

Genotropin has active ingredients of somatropin recombinant. It is often used in growth hormone deficiency. eHealthMe is studying from 41,924 Genotropin users. Check the latest studies of Genotropin.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.



On Jul, 13, 2026

72 people who take Genotropin and Ranitidine together, and have interactions are studied.

Genotropin and Ranitidine drug interactions.

What are the common drug interactions of Genotropin and Ranitidine, by gender? *:

female:

  1. Infusion related reaction
  2. Joint swelling
  3. Peripheral swelling
  4. Rib fracture
  5. Spinal column injury (spinal cord bone injury)
  6. Vasculitis (inflammation of a blood vessel or blood vessels)
  7. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  8. Pyrexia (fever)
  9. Sluggishness (lacking alertness)
  10. Anxiety

male:

  1. Heart rate increased
  2. Respiratory rate increased (excess breathing rate/min)
  3. Injection site pain
  4. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
  5. Respiratory syncytial virus bronchiolitis (a lower respiratory tract infection due to virus)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)
  7. Dyspnoea (difficult or laboured respiration)
  8. Enuresis (repeated inability to control urination)
  9. Hemiparesis (weakness on one side of the body)
  10. Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)

What are the common drug interactions of Genotropin and Ranitidine, by age (0-1 to 60+)? *:

0-1:

  1. Heart rate increased
  2. Respiratory rate increased (excess breathing rate/min)
  3. Ear infection
  4. Respiratory distress (difficulty in breathing)
  5. Rhinovirus infection
  6. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
  7. Respiratory syncytial virus bronchiolitis (a lower respiratory tract infection due to virus)
  8. Tension (the act or process of stretching something tight)
  9. Pyrexia (fever)
  10. Sluggishness (lacking alertness)

2-9:

  1. Mood altered (changes in mood)
  2. Self injurious behaviour
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Injection site pain
  5. Vomiting
  6. Personality change
  7. Death
  8. Femur fracture

10-19:

  1. Headache (pain in head)
  2. Multi-organ failure (multisystem organ failure)
  3. Sepsis (a severe blood infection that can lead to organ failure and death)
  4. Enuresis (repeated inability to control urination)
  5. Hemiparesis (weakness on one side of the body)
  6. Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)
  7. Vision blurred
  8. Vomiting
  9. Death
  10. Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)

20-29:

  1. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)

30-39:

  1. Depression
  2. Neuralgia (pain in one or more nerves)

40-49:

  1. Chest pain
  2. Constipation
  3. Head discomfort
  4. Headache (pain in head)
  5. Insomnia (sleeplessness)
  6. Palpitations (feelings or sensations that your heart is pounding or racing)
  7. Arthralgia (joint pain)
  8. Death
  9. Drug ineffective
  10. Infusion related reaction

50-59:

  1. Alopecia (absence of hair from areas of the body)
  2. Alveolar osteitis (complication of wound healing following extraction of a tooth)
  3. Asthenia (weakness)
  4. Barrett's oesophagus (barrett's oesophagus is a disorder in which the lining of the oesophagus (the tube that carries food from the throat to the stomach) is damaged by stomach acid and changed to a lining similar to that of the stomach)
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Burning sensation
  7. Dental caries
  8. Drug ineffective
  9. Exostosis (formation of new bone on the surface of a bone)
  10. Fatigue (feeling of tiredness)

60+:

  1. Chest pain
  2. Abdominal distension
  3. Blood pressure increased
  4. Cardiac disorder
  5. Deafness
  6. Diaphragmatic hernia (defect or hole in the diaphragm that allows the abdominal contents to move into the chest cavity)
  7. Dyspnoea (difficult or laboured respiration)
  8. Headache (pain in head)
  9. Hypotension (abnormally low blood pressure)
  10. Insomnia (sleeplessness)

What are the existing conditions these people have? *

  1. Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 11 people, 15.28%
  2. Primary Hypothyroidism (failure of the thyroid gland to produce or release thyroid hormones into the bloodstream): 11 people, 15.28%
  3. Thyroid Diseases: 9 people, 12.50%
  4. Stable Angina (a constant chest pain): 7 people, 9.72%
  5. Oesophagitis (inflammation of oesophagus): 6 people, 8.33%
  6. Thrombophlebitis (swelling (inflammation) of a vein caused by a blood clot): 6 people, 8.33%
  7. Vitamin B12 Deficiency: 5 people, 6.94%
  8. Hypothalamo-Pituitary Disorder (loss of function in an endocrine gland due to failure of the pituitary gland to secrete hormones which stimulate that gland's function): 5 people, 6.94%
  9. Vitamin B Complex Deficiency: 5 people, 6.94%
  10. Body Height Below Normal: 5 people, 6.94%

* Approximation only. Some reports may have incomplete information.

Do you take Genotropin and Ranitidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Genotropin and Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Genotropin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Genotropin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranitidine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on somatropin recombinant and ranitidine (the active ingredients of Genotropin and Ranitidine, respectively), and Genotropin and Ranitidine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: